Bayesian adaptive dose‐escalation designs for simultaneously estimating the optimal and maximum safe dose based on safety and efficacy |
| |
| Authors: | Wai Yin Yeung Bruno Reigner Ulrich Beyer Cheikh Diack Daniel Sabanés bové Giuseppe Palermo Thomas Jaki |
| |
| Affiliation: | 1. Department of Biostatistics, Hoffmann‐la Roche LTD/Roche Products Limited, United Kingdom;2. Department of Clinical Pharmacology, Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland;3. Department of Biostatistics, Hoffmann‐la Roche LTD, Basel, Switzerland;4. Medical and Pharmaceutical Statistics Research Unit, Department of Mathematics and Statistics, Fylde College, Lancaster University, Lancaster, United Kingdom |
| |
| Abstract: | The main purpose of dose‐escalation trials is to identify the dose(s) that is/are safe and efficacious for further investigations in later studies. In this paper, we introduce dose‐escalation designs that incorporate both the dose‐limiting events and dose‐limiting toxicities (DLTs) and indicative responses of efficacy into the procedure. A flexible nonparametric model is used for modelling the continuous efficacy responses while a logistic model is used for the binary DLTs. Escalation decisions are based on the combination of the probabilities of DLTs and expected efficacy through a gain function. On the basis of this setup, we then introduce 2 types of Bayesian adaptive dose‐escalation strategies. The first type of procedures, called “single objective,” aims to identify and recommend a single dose, either the maximum tolerated dose, the highest dose that is considered as safe, or the optimal dose, a safe dose that gives optimum benefit risk. The second type, called “dual objective,” aims to jointly estimate both the maximum tolerated dose and the optimal dose accurately. The recommended doses obtained under these dose‐escalation procedures provide information about the safety and efficacy profile of the novel drug to facilitate later studies. We evaluate different strategies via simulations based on an example constructed from a real trial on patients with type 2 diabetes, and the use of stopping rules is assessed. We find that the nonparametric model estimates the efficacy responses well for different underlying true shapes. The dual‐objective designs give better results in terms of identifying the 2 real target doses compared to the single‐objective designs. |
| |
| Keywords: | Bayesian approach dose‐escalation procedures dose‐limiting event efficacy flexible efficacy model gain function stopping rules |
|
|
